You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

poorly differentiated neuroendocrine carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Oncology, Neuroendocrine Carcinoma Trial in United Kingdom (Liposomal Irinotecan, Fluorouracil, Folinic Acid)

Active, not recruiting
  • Oncology
  • Neuroendocrine Carcinoma
  • Liposomal Irinotecan
  • +3 more
  • Glasgow, United Kingdom
  • +3 more
Dec 2, 2022

GEP-NET Trial in Taiwan (nanoliposomal irinotecan plus carboplatin)

Not yet recruiting
  • GEP-NET
  • nanoliposomal irinotecan plus carboplatin
  • Kaohsiung, Taiwan
  • +5 more
May 17, 2022

Neuroendocrine Carcinoma Trial in France (Nivolumab, Ipilimumab)

Active, not recruiting
  • Neuroendocrine Carcinoma
  • Aix-en-Provence, France
  • +6 more
Mar 9, 2022

Neuroendocrine Carcinoma Trial in France (FOLFOXIRI Protocol, Cisplatin injection)

Recruiting
  • Neuroendocrine Carcinoma
  • FOLFOXIRI Protocol
  • Cisplatin injection
  • Caen, France
  • +5 more
Apr 13, 2021

Neuroendocrine Tumours (NET), Neuroendocrine Carcinomas (NEC) Trial in Spain (177Lu-Dotatate, Nivolumab)

Recruiting
  • Neuroendocrine Tumours (NET)
  • Neuroendocrine Carcinomas (NEC)
  • Santiago De Compostela, Galicia, Spain
  • +4 more
Aug 1, 2022

Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Tumor, Metastatic Neuroendocrine Carcinoma Trial in United

Recruiting
  • Metastatic Lung Small Cell Carcinoma
  • +16 more
  • Phoenix, Arizona
  • +10 more
Mar 25, 2022

Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1

Completed
  • Poorly Differentiated Malignant Neuroendocrine Carcinoma
  • +4 more
  • Everolimus (Afinitor®)
  • Berlin, Germany
    Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatolog
Oct 27, 2020

Neuroendocrine Carcinomas Trial in France (Folfiri-bevacizumab, Folfiri)

Recruiting
  • Neuroendocrine Carcinomas
  • Amiens, France
  • +26 more
Jan 26, 2022

Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Tumor Trial in

Active, not recruiting
  • Metastatic Large Cell Neuroendocrine Carcinoma
  • +3 more
  • Cabozantinib S-malate
  • +2 more
  • Birmingham, Alabama
  • +46 more
Dec 30, 2022

Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin,

Completed
Has Results
  • Well-differentiated Non-functional NET of Thoracic Origin
  • +3 more
  • Duarte, California
  • +34 more
Mar 16, 2021

Head and Neck Squamous Cell Carcinoma Trial (Pembrolizumab, Cisplatin, Paclitaxel-albumin)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 25, 2023

Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Carcinoma Trial in United States (Lurbinectedin)

Recruiting
  • Advanced Solid Tumor
  • +4 more
  • Stanford, California
  • +15 more
Dec 21, 2022

Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site Trial in San

Not yet recruiting
  • Neuroendocrine Tumors
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Feb 17, 2023

Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer Trial in Tampa (Pembrolizumab, Lenvatinib)

Active, not recruiting
  • Neuroendocrine Tumors
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 24, 2023

Extrapulmonary Small Cell Neuroendocrine Carcinoma, Recurrent Extrapulmonary Small Cell Neuroendocrine Carcinoma, Recurrent

Recruiting
  • Advanced Extrapulmonary Neuroendocrine Carcinoma
  • +3 more
  • Atezolizumab
  • +7 more
  • Phoenix, Arizona
  • +105 more
Jan 24, 2023

Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma Trial (Atezolizumab, Tiragolumab)

Recruiting
  • Atypical Teratoid/Rhabdoid Tumor
  • +17 more
  • Atezolizumab
  • +7 more
  • Birmingham, Alabama
  • +19 more
Feb 2, 2023

Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic

Active, not recruiting
  • Columnar Cell Variant Thyroid Gland Papillary Carcinoma
  • +25 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Torrance, California
  • +6 more
Jan 12, 2023

Neuroendocrine Carcinoma Trial in Toronto (Avelumab)

Completed
  • Neuroendocrine Carcinoma
  • Toronto, Ontario, Canada
    Sunnybrook Health Sciences Centre
Mar 17, 2020

Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma Trial (Lutetium Lu 177 Dotatate,

Not yet recruiting
  • Metastatic Pancreatic Neuroendocrine Tumor
  • Unresectable Pancreatic Neuroendocrine Carcinoma
  • Lutetium Lu 177 Dotatate
  • +4 more
  • (no location specified)
Feb 10, 2022

Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer Trial in New York, Houston (AIC100 CAR T

Recruiting
  • Anaplastic Thyroid Cancer
  • Relapsed/Refractory Poorly Differentiated Thyroid Cancer
  • AIC100 CAR T Cells
  • New York, New York
    Weill Cornell Medical College
Feb 14, 2022

Differentiated Thyroid Cancer (DTC), Poorly Differentiated Thyroid Cancer Trial in Philadelphia (Cabozantinib)

Active, not recruiting
  • Differentiated Thyroid Cancer (DTC)
  • Poorly Differentiated Thyroid Cancer
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Oct 7, 2021

Pancreatic Cancer Dietary Assessment Study

Completed
  • Pancreatic Neoplasm
  • +3 more
  • Pancreo-KIT breath test
  • Manchester, United Kingdom
    The Christie NHS Foundation Trust
Feb 1, 2022

Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma by AJCC V8

Suspended
  • Metastatic Thyroid Gland Carcinoma
  • +2 more
  • Saint Petersburg, Russian Federation
    Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of H
May 13, 2021

Malignant Thyroid Gland Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma Trial in Houston

Recruiting
  • Malignant Thyroid Gland Neoplasm
  • +6 more
  • Quality-of-Life Assessment
  • +3 more
  • Ann Arbor, Michigan
  • +1 more
Jan 24, 2023

Carcinoma, Neuroendocrine Trial in Canton (Selinexor)

Completed
  • Carcinoma, Neuroendocrine
  • Canton, Ohio
    Gabrail Cancer Center Research
Sep 13, 2019